ABBV — AbbVie Inc. catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

15 verified catalyst event(s) for AbbVie Inc. (ticker ABBV). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2026-12-01 — Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subr · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-12 (month) in 27d ESTIMATED	READOUT Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administere Phase 2/3 · AMD, nAMD	ABBV AbbVie Inc.	ABBV-RGX-314, ABBV-RGX-314, Ranibizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12 (month) in 27d ESTIMATED	READOUT Study to Assess Adverse Events and Change in Disease Activity in Previously Trea Phase 2 · Unresectable Metastatic Colorectal Cancer	ABBV AbbVie Inc.	ABBV-400, Bevacizumab, Folinic Acid, Flu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12 (month) in 27d ESTIMATED	READOUT A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adoles Phase 3 · Hidradenitis Suppurativa	ABBV AbbVie Inc.	Lutikizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Li Phase 2/3 · Hepatocellular Carcinoma	ABBV AbbVie Inc.	Livmoniplimab, Budigalimab, Durvalumab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids Phase 3 · Atopic Dermatitis	ABBV AbbVie Inc.	Upadacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02 (month) in 3mo ESTIMATED	READOUT IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants Wi Phase 1/2 · Acute Myeloid Leukemia	ABBV AbbVie Inc.	Azacitidine, IMGN632, Venetoclax	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02 (month) in 3mo ESTIMATED	READOUT A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirve Phase 2 · Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive	ABBV AbbVie Inc.	Mirvetuximab Soravtansine, Lubricating E	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02 (month) in 3mo ESTIMATED	READOUT A Study to Assess Molecular Changes in Adult Participants With Moderate to Sever Phase 2 · Hidradenitis Suppurativa, Atopic Dermatitis	ABBV AbbVie Inc.	Lutikizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02 (month) in 3mo ESTIMATED	READOUT A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo i Phase 2 · Migraine	ABBV AbbVie Inc.	MEDI0618	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02 (month) in 3mo ESTIMATED	READOUT A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Ar Phase 2 · Rheumatoid Arthritis	ABBV AbbVie Inc.	Lutikizumab, Ravagalimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-03 (month) in 4mo ESTIMATED	READOUT A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Carip Phase 3 · Depression, Bipolar I Disorder	ABBV AbbVie Inc.	Cariprazine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-03 (month) in 4mo ESTIMATED	READOUT Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacit Phase 3 · Systemic Lupus Erythematosus	ABBV AbbVie Inc.	Upadacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-03 (month) in 4mo ESTIMATED	READOUT A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Phase 3 · Crohn's Disease	ABBV AbbVie Inc.	Risankizumab SC	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-03 (month) in 4mo ESTIMATED	READOUT Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous Phase 2 · Urothelial Carcinoma	ABBV AbbVie Inc.	Livmoniplimab, Budigalimab, Docetaxel, P	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-03 (month) in 4mo ESTIMATED	READOUT Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With D Phase 2 · Bipolar I or II Disorder	ABBV AbbVie Inc.	ABBV-932	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change